2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
63
Precursor Cell Lymphoblastic Leukemia-Lymphoma
52
Leukemia, Myeloid, Chronic-Phase
34
Leukemia
30
Leukemia, Myeloid, Acute
18
Breast Neoplasms
18
Recurrence
15
Prostatic Neoplasms
14
Leukemia, Lymphocytic, Chronic, B-Cell
13
Neoplasm Metastasis
12
Blast Crisis
12
Multiple Myeloma
11
Carcinoma, Non-Small-Cell Lung
11
Burkitt Lymphoma
11
Pancreatic Neoplasms
10
Neoplasms
9
Leukemia, Myeloid, Accelerated Phase
9
Lung Neoplasms
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Non-Hodgkin
7
Glioblastoma
7
Melanoma
6
Lymphoma
6
Glioma
6
Rectal Neoplasms
5
Philadelphia Chromosome
5
Ovarian Neoplasms
5
Myelodysplastic Syndromes
5
Lymphoma, Large B-Cell, Diffuse
5
Hematologic Neoplasms
5
Interventions
salicylhydroxamic acid
1
nilotinib
1
morphine, naltrexone combination
1
Naltrexone
1
Morphine
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Substance Withdrawal Syndrome
×
Dasatinib
×
Clear all
NCT04147533
2024-11-26
HALF
Masaryk University
Phase 2
Active not recruiting
150 enrolled